These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17105367)

  • 21. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploiting receptor tyrosine kinase co-activation for cancer therapy.
    Tan AC; Vyse S; Huang PH
    Drug Discov Today; 2017 Jan; 22(1):72-84. PubMed ID: 27452454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.
    Noonberg SB; Benz CC
    Drugs; 2000 Apr; 59(4):753-67. PubMed ID: 10804033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
    Ghosh S; Marrocco I; Yarden Y
    Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.
    Zarei O; Benvenuti S; Ustun-Alkan F; Hamzeh-Mivehroud M; Dastmalchi S
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2429-2446. PubMed ID: 27503093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic lymphoma kinase as a therapeutic target.
    Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
    Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of erbB tyrosine kinase inhibitors.
    Fry DW
    Exp Cell Res; 2003 Mar; 284(1):131-9. PubMed ID: 12648472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaplastic lymphoma kinase inhibitors.
    Crescenzo R; Inghirami G
    Curr Opin Pharmacol; 2015 Aug; 23():39-44. PubMed ID: 26051994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
    Hojjat-Farsangi M
    J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting ERBB receptors in cancer.
    Hynes NE
    Recent Results Cancer Res; 2007; 172():45-57. PubMed ID: 17607935
    [No Abstract]   [Full Text] [Related]  

  • 32. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
    Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells.
    Maina F
    Curr Med Chem; 2014; 21(14):1607-17. PubMed ID: 23992334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
    Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
    Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour-agnostic drugs and future cancer treatment.
    Børset M
    Tidsskr Nor Laegeforen; 2019 Mar; 139(5):. PubMed ID: 30872821
    [No Abstract]   [Full Text] [Related]  

  • 37. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer.
    Jin N; Bi A; Lan X; Xu J; Wang X; Liu Y; Wang T; Tang S; Zeng H; Chen Z; Tan M; Ai J; Xie H; Zhang T; Liu D; Huang R; Song Y; Leung EL; Yao X; Ding J; Geng M; Lin SH; Huang M
    Nat Commun; 2019 Jun; 10(1):2701. PubMed ID: 31221965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel FLT3 tyrosine kinase inhibitors.
    Levis M; Small D
    Expert Opin Investig Drugs; 2003 Dec; 12(12):1951-62. PubMed ID: 14640939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic targeting of receptor tyrosine kinases in lung cancer.
    Choong NW; Ma PC; Salgia R
    Expert Opin Ther Targets; 2005 Jun; 9(3):533-59. PubMed ID: 15948672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging drugs for targeted therapy of bladder cancer.
    Agarwal PK; Black PC; McConkey DJ; Dinney CP
    Expert Opin Emerg Drugs; 2007 Sep; 12(3):435-48. PubMed ID: 17874971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.